Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

As we say our goodbyes to 2025, we must bid adieu to the memes that came with it. It was a surreal year on the internet — many of this year’s memes leaned heavily into the brain rot that’s come with ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Stay up to date on all meme stocks with Benzinga Pro, your go-to stock market research platform with real-time news and actionable insights. Many trends and fads in investing capture the attention of ...

It isn’t yet possible to diagnose chronic traumatic encephalopathy—more widely known as CTE—in the living. Yet for many people, especially athletes, the fear is real. In fact, 1 in 3 former NFL ...

The biggest stories of the day delivered to your inbox.